PA
LXRX icon

Parallel Advisors’s Lexicon Pharmaceuticals LXRX Stock Holding History

Parallel Advisors’s Portfolio LXRX Stock Details LXRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$385 Buy
+247
New +$359 ﹤0.01% 3714
2018
Q1 		– Sell
-198
Closed -$2K – 2136
2017
Q4 		$2K Buy
+198
New +$2.06K ﹤0.01% 1861

Other funds holding LXRX

AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
SC
Sessa Capital New York $5.51B AUM 47.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Parallel Advisors's LXRX Position: Q1 2026 in Review

Parallel Advisors opened a new position in Lexicon Pharmaceuticals (LXRX) in Q1 2026: 247 shares worth $385. The stake represents ﹤0.01% of the portfolio and ranks #3714 among its holdings. This is a return to the name: Parallel Advisors previously reported a position in LXRX as recently as Q4 2017.

Parallel Advisors first reported a position in LXRX in Q4 2017 and has held it in 2 quarters since. The position peaked at $2K in Q4 2017. 136 funds tracked by Wall St. Rank hold LXRX as of Q1 2026.

  • Parallel Advisors held 247 shares of Lexicon Pharmaceuticals worth $385 as of Q1 2026.
  • Lexicon Pharmaceuticals was a new Parallel Advisors position in Q1 2026.
  • Lexicon Pharmaceuticals made up ﹤0.01% of Parallel Advisors's portfolio in Q1 2026, its #3714 holding.
  • Parallel Advisors first reported a position in Lexicon Pharmaceuticals in Q4 2017 and has held it in 2 quarters since.
  • Parallel Advisors's Lexicon Pharmaceuticals position peaked at $2K in Q4 2017.
  • 136 funds tracked by Wall St. Rank held Lexicon Pharmaceuticals as of Q1 2026.

Based on Parallel Advisors's 13F filing for Q1 2026, filed 7 May 2026.